Uterine fibroids are benign gynecologic tumors, and women aged between 30 to 50 years are known to have a high incidence of uterine fibroids. A growing number of pharmacotherapies and minimally invasive organ-preserving treatments have been designed and conducted over the past few years. However, there has not been any therapeutic drugs exhibiting an ideal therapeutic effect and low recurrence rate, such that the surgical treatment continues to be primarily employed in the actual clinical treatment. In general, surgical treatment has been performed as the organ- and fertility-preserving hysteroscopic or laparoscopic resections of the fibroids. Minimally invasive surgical equipment (e.g., hysteroscopy, traditional porous laparoscopy, trans-umbilical laparoscopy, transvaginal laparoscopy, as well as robot-assisted laparoscopy) has been extensively applied to clinical treatment. Compared with traditional laparotomy, minimally invasive surgical equipment is characterized by minimally invasive surgery, high efficiency and safety. As medical technology has been leaping forward, interventional therapy and radiofrequency ablation can also be employed for treating uterine fibroids. In accordance with the research progress worldwide, the current situation, limitations, and advantages of the treatment of uterine fibroids in patients with fertility requirements are reviewed in this study.
{"title":"Conservative surgical treatment of uterine fibroids in women of childbearing age","authors":"","doi":"10.22514/ejgo.2023.053","DOIUrl":"https://doi.org/10.22514/ejgo.2023.053","url":null,"abstract":"Uterine fibroids are benign gynecologic tumors, and women aged between 30 to 50 years are known to have a high incidence of uterine fibroids. A growing number of pharmacotherapies and minimally invasive organ-preserving treatments have been designed and conducted over the past few years. However, there has not been any therapeutic drugs exhibiting an ideal therapeutic effect and low recurrence rate, such that the surgical treatment continues to be primarily employed in the actual clinical treatment. In general, surgical treatment has been performed as the organ- and fertility-preserving hysteroscopic or laparoscopic resections of the fibroids. Minimally invasive surgical equipment (e.g., hysteroscopy, traditional porous laparoscopy, trans-umbilical laparoscopy, transvaginal laparoscopy, as well as robot-assisted laparoscopy) has been extensively applied to clinical treatment. Compared with traditional laparotomy, minimally invasive surgical equipment is characterized by minimally invasive surgery, high efficiency and safety. As medical technology has been leaping forward, interventional therapy and radiofrequency ablation can also be employed for treating uterine fibroids. In accordance with the research progress worldwide, the current situation, limitations, and advantages of the treatment of uterine fibroids in patients with fertility requirements are reviewed in this study.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This research aims to investigate the effect of ultrasound-guided continuous thoracic paravertebral nerve block in patients undergoing radical mastectomy. Ninety-six patients who underwent radical mastectomy were equally divided into a study group (administered with a continuous thoracic paravertebral nerve block and general anesthesia) and a control group (given conventional general anesthesia) with a random number table. At T2–T4 (T2: immediate tracheal intubation; T3: at skin incision; T4: at extubation), mean artery pressure (MAP) and hear rate (HR) were significantly lower in the study group (p < 0.05); however, there was no significant difference in blood oxygen saturation (SpO2) between the two groups at different time points. At T2–T4, cortisol (Cor) levels were significantly lower in the study group (p < 0.05). At T0–T2, there was no significant difference in the levels of adrenocorticotropic hormone (ACTH) between the two groups. At T3–T4, the levels of ACTH in the study group were significantly lower (p < 0.05). There were no significant differences in blood pressure between the two groups at any time point. At the moment of discharge from the resuscitation room and 2 hours after surgery, the numerical rating scale (NRS) score in the study group was significantly reduced (p < 0.05). The incidence of adverse reactions in the study group was 10.42%; this was lower than that in the control group (33.33%) (p < 0.05). Finally, the use of fentanyl and propofol, and the frequency of analgesic pump use, were significantly lower in the study group (p < 0.05). Ultrasound-guided thoracic paravertebral nerve block can effectively maintain hemodynamic stability, improve the stress response, reduce postoperative pain, reduce the use of anesthetic drugs, and effectively control the incidence of adverse reactions in patients undergoing radical mastectomy.
{"title":"Ultrasound-guided thoracic paravertebral nerve block in patients undergoing radical mastectomy","authors":"","doi":"10.22514/ejgo.2023.083","DOIUrl":"https://doi.org/10.22514/ejgo.2023.083","url":null,"abstract":"This research aims to investigate the effect of ultrasound-guided continuous thoracic paravertebral nerve block in patients undergoing radical mastectomy. Ninety-six patients who underwent radical mastectomy were equally divided into a study group (administered with a continuous thoracic paravertebral nerve block and general anesthesia) and a control group (given conventional general anesthesia) with a random number table. At T2–T4 (T2: immediate tracheal intubation; T3: at skin incision; T4: at extubation), mean artery pressure (MAP) and hear rate (HR) were significantly lower in the study group (p < 0.05); however, there was no significant difference in blood oxygen saturation (SpO2) between the two groups at different time points. At T2–T4, cortisol (Cor) levels were significantly lower in the study group (p < 0.05). At T0–T2, there was no significant difference in the levels of adrenocorticotropic hormone (ACTH) between the two groups. At T3–T4, the levels of ACTH in the study group were significantly lower (p < 0.05). There were no significant differences in blood pressure between the two groups at any time point. At the moment of discharge from the resuscitation room and 2 hours after surgery, the numerical rating scale (NRS) score in the study group was significantly reduced (p < 0.05). The incidence of adverse reactions in the study group was 10.42%; this was lower than that in the control group (33.33%) (p < 0.05). Finally, the use of fentanyl and propofol, and the frequency of analgesic pump use, were significantly lower in the study group (p < 0.05). Ultrasound-guided thoracic paravertebral nerve block can effectively maintain hemodynamic stability, improve the stress response, reduce postoperative pain, reduce the use of anesthetic drugs, and effectively control the incidence of adverse reactions in patients undergoing radical mastectomy.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aimed to investigate the effects of different doses of esketamine on hemodynamic indicators, pain stress indicators and Visual Analog Scale (VAS) scores in patients undergoing laparoscopic resection for benign ovarian tumors induced by remifentanil. A total of 110 patients with benign ovarian tumors scheduled for laparoscopic resection between June and December 2023 were included in the study and divided into three groups: Group A (35 cases), Group B (37 cases), and Group C (38 cases), based on their anesthesia regimen. Anesthesia induction for all groups included propofol, remifentanil, and cisatracurium. Group A received an intravenous dose of 0.8 mg/kg esketamine, Group B received 0.6 mg/kg esketamine and Group C did not receive esketamine. The results revealed statistically significant differences in average arterial pressure and heart rate at various time points within each group (p < 0.05), and significant differences were observed in Substance P (SP) and Prostaglandin E2 (PEG2) at three different time points within each group (p < 0.05). VAS scores during and after surgery at 6 and 12 hours significantly differed among the three groups (p < 0.05). There was a significant difference in awakening time among the three groups (p < 0.05). However, there were no statistically significant differences in the incidence of adverse reactions among the three groups (p > 0.05). In conclusion, both 0.6 mg/kg and 0.8 mg/kg doses of esketamine effectively prevented remifentanil-induced hyperalgesia in patients undergoing laparoscopic resection for benign ovarian tumors, significantly reducing patient pain. Notably, the 0.6 mg/kg dose of esketamine demonstrated better hemodynamic stability, promoted patient recovery, and showed superior clinical utility compared to the 0.8 mg/kg dose.
{"title":"Effects of different doses of esketamine on hemodynamic indexes, pain stress indexes, and VAS scores in patients with benign ovarian tumors undergoing laparoscopic resection induced by remifentanil","authors":"","doi":"10.22514/ejgo.2023.082","DOIUrl":"https://doi.org/10.22514/ejgo.2023.082","url":null,"abstract":"This study aimed to investigate the effects of different doses of esketamine on hemodynamic indicators, pain stress indicators and Visual Analog Scale (VAS) scores in patients undergoing laparoscopic resection for benign ovarian tumors induced by remifentanil. A total of 110 patients with benign ovarian tumors scheduled for laparoscopic resection between June and December 2023 were included in the study and divided into three groups: Group A (35 cases), Group B (37 cases), and Group C (38 cases), based on their anesthesia regimen. Anesthesia induction for all groups included propofol, remifentanil, and cisatracurium. Group A received an intravenous dose of 0.8 mg/kg esketamine, Group B received 0.6 mg/kg esketamine and Group C did not receive esketamine. The results revealed statistically significant differences in average arterial pressure and heart rate at various time points within each group (p < 0.05), and significant differences were observed in Substance P (SP) and Prostaglandin E2 (PEG2) at three different time points within each group (p < 0.05). VAS scores during and after surgery at 6 and 12 hours significantly differed among the three groups (p < 0.05). There was a significant difference in awakening time among the three groups (p < 0.05). However, there were no statistically significant differences in the incidence of adverse reactions among the three groups (p > 0.05). In conclusion, both 0.6 mg/kg and 0.8 mg/kg doses of esketamine effectively prevented remifentanil-induced hyperalgesia in patients undergoing laparoscopic resection for benign ovarian tumors, significantly reducing patient pain. Notably, the 0.6 mg/kg dose of esketamine demonstrated better hemodynamic stability, promoted patient recovery, and showed superior clinical utility compared to the 0.8 mg/kg dose.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this study, it was planned to investigate the effects of ascites and sarcopenia on treatment toxicity, disease free survival (DFS) and disease specific survival (DSS) times in a population of patients with stage 3–4 ovarian cancer. In this retrospective study that include 80 patients treated and followed-up for advanced stage ovarian cancer in a university hospital between 2012–2019, ascites volumes and sarcopenia indices of the patients were calculated by computed tomography from medical patient records, and their clinico-pathologic characteristics as well as laboratory variables were reviewed. The median survival was 30.10 ± 2.85 months for the patients with ascites and 54.26 ± 4.16 months without ascites (p < 0.001). The duration of DSS was found to be negatively affected in patients with ascites (Hazard Ratio (HR): 3.048), prognostic nutritional index (PNI) <47.5 (HR: 2.528), platelet (PLT) >338,000 (HR: 1.936), lactate dehydrogenase (LDH) value >320 (HR: 1.624), albumin value <4 (HR: 1.849). When factors that are found to have a significant relationship with DSS were assessed according to multivariate Cox regression analysis, the presence of ascites was identified as an independent risk factor associated with DSS (p: 0.004). The risk of developing grade 2 or 3 neutropenia, anemia and thrombocytopenia is significantly increased following the first chemotherapy course in patients with ascites when compared to those without ascites (p: 0.006). The presence of ascites in patients with ovarian cancer is a risk factor associated with chemotherapy toxicity and reduced survival.
{"title":"Evaluation of the relationship of the amount of ascites as measured quantitatively using computed tomography with chemotherapy toxicity in patients with ovarian cancer","authors":"","doi":"10.22514/ejgo.2023.078","DOIUrl":"https://doi.org/10.22514/ejgo.2023.078","url":null,"abstract":"In this study, it was planned to investigate the effects of ascites and sarcopenia on treatment toxicity, disease free survival (DFS) and disease specific survival (DSS) times in a population of patients with stage 3–4 ovarian cancer. In this retrospective study that include 80 patients treated and followed-up for advanced stage ovarian cancer in a university hospital between 2012–2019, ascites volumes and sarcopenia indices of the patients were calculated by computed tomography from medical patient records, and their clinico-pathologic characteristics as well as laboratory variables were reviewed. The median survival was 30.10 ± 2.85 months for the patients with ascites and 54.26 ± 4.16 months without ascites (p < 0.001). The duration of DSS was found to be negatively affected in patients with ascites (Hazard Ratio (HR): 3.048), prognostic nutritional index (PNI) <47.5 (HR: 2.528), platelet (PLT) >338,000 (HR: 1.936), lactate dehydrogenase (LDH) value >320 (HR: 1.624), albumin value <4 (HR: 1.849). When factors that are found to have a significant relationship with DSS were assessed according to multivariate Cox regression analysis, the presence of ascites was identified as an independent risk factor associated with DSS (p: 0.004). The risk of developing grade 2 or 3 neutropenia, anemia and thrombocytopenia is significantly increased following the first chemotherapy course in patients with ascites when compared to those without ascites (p: 0.006). The presence of ascites in patients with ovarian cancer is a risk factor associated with chemotherapy toxicity and reduced survival.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endometrial carcinoma (EC) is a type of epithelial malignancy prevalent in about 8% of the total malignancies in women. Development of new treatment methods is vital for improving the prognosis of endometrial cancer. High Intensity Focused Ultrasound (HIFU) is a safe method for oncological treatment with low complication rate. However, EC treatment by HIFU is rarely reported and its mechanism is unclear. Herein, the effects of HIFU on EC progression were detected. Data confirmed the inhibition of EC tumor growth in mice by HIFU. Moreover, HIFU inhibited the EC tumor apoptosis. It down-regulated the Treg cell production and enhanced the tumor-specific cytotoxicity. It restrained the Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3) pathway in viv
子宫内膜癌(EC)是一种常见的上皮恶性肿瘤,约占女性恶性肿瘤总数的8%。发展新的治疗方法对改善子宫内膜癌的预后至关重要。高强度聚焦超声(HIFU)是一种安全、低并发症的肿瘤治疗方法。然而,HIFU治疗EC的报道很少,其机制尚不清楚。本研究检测了HIFU对EC进展的影响。数据证实HIFU对小鼠EC肿瘤生长有抑制作用。HIFU对EC肿瘤的凋亡有抑制作用。下调Treg细胞的产生,增强肿瘤特异性细胞毒性。在体外抑制Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3)通路
{"title":"Tumor growth inhibition and tumor specific immunity enhancement in endometrial carcinoma by high intensity focused ultrasound","authors":"","doi":"10.22514/ejgo.2023.085","DOIUrl":"https://doi.org/10.22514/ejgo.2023.085","url":null,"abstract":"Endometrial carcinoma (EC) is a type of epithelial malignancy prevalent in about 8% of the total malignancies in women. Development of new treatment methods is vital for improving the prognosis of endometrial cancer. High Intensity Focused Ultrasound (HIFU) is a safe method for oncological treatment with low complication rate. However, EC treatment by HIFU is rarely reported and its mechanism is unclear. Herein, the effects of HIFU on EC progression were detected. Data confirmed the inhibition of EC tumor growth in mice by HIFU. Moreover, HIFU inhibited the EC tumor apoptosis. It down-regulated the Treg cell production and enhanced the tumor-specific cytotoxicity. It restrained the Janus kinase/Signal transducer and activator of transcription 3 (JAK/STAT3) pathway in viv","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136368237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endometrial cancer (EC) is one of the three main gynecological cancers. Identifying new therapeutic targets and further elucidating the molecular mechanisms of EC tumorigenesis have important implications for women’s health. The Go-Ichi-Ni-San (GINS) family, which includes four subunits (GINS1–4), has specific functions in DNA replication and cell cycle. The Cancer Genome Atlas (TCGA) data showed that GINS2 transcription level is upregulated in endometrial cancer tissue. However, the possible role of GINS2 in EC progression is still unknown. Herein, we explored the role of GINS2 in EC. We noticed that GINS2 was overexpressed in EC cells. GINS2 knockdown suppressed the proliferation of EC cells and induced cell cycle arrest. We further noticed that GINS2 knockdown restrained the Epithelial mesenchymal transformation (EMT) of EC cells. Mechanically, its downregulation suppressed the extracellular regulated protein kinase (ERK)/Microtubule-Associated Protein Kinase (MAPK) pathway, thereby suppressing EC progression. Thus, GINS2 has the potential to act as a therapeutic target for EC.
{"title":"GINS2 regulates epithelial mesenchymal transformation and cell cycle in endometrial carcinoma by stimulating ERK/MAPK signaling","authors":"","doi":"10.22514/ejgo.2023.067","DOIUrl":"https://doi.org/10.22514/ejgo.2023.067","url":null,"abstract":"Endometrial cancer (EC) is one of the three main gynecological cancers. Identifying new therapeutic targets and further elucidating the molecular mechanisms of EC tumorigenesis have important implications for women’s health. The Go-Ichi-Ni-San (GINS) family, which includes four subunits (GINS1–4), has specific functions in DNA replication and cell cycle. The Cancer Genome Atlas (TCGA) data showed that GINS2 transcription level is upregulated in endometrial cancer tissue. However, the possible role of GINS2 in EC progression is still unknown. Herein, we explored the role of GINS2 in EC. We noticed that GINS2 was overexpressed in EC cells. GINS2 knockdown suppressed the proliferation of EC cells and induced cell cycle arrest. We further noticed that GINS2 knockdown restrained the Epithelial mesenchymal transformation (EMT) of EC cells. Mechanically, its downregulation suppressed the extracellular regulated protein kinase (ERK)/Microtubule-Associated Protein Kinase (MAPK) pathway, thereby suppressing EC progression. Thus, GINS2 has the potential to act as a therapeutic target for EC.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To analyze the effect of applying health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery. We recruited 130 patients with cervical cancer who underwent gynecological surgery in our hospital between the 01 February 2021 and the 01 March 2022. According to the random number table method, the patients were divided into a control group and an observation group (65 cases per group). The control group received routine health education, while the observation group received health education based on the integrated theory of health behavior change. We compared the two groups with regards to pelvic floor function, quality-of-life, and psychological status before and after intervention by analyzing PFDI-20 (Pelvic Floor Distress Inventory Questionnaire-20), PFIQ-7 (Pelvic Floor Impact Questionnaire-7), HAMA (Hamilton Anxiety Scale) and HAMD (Hamilton Depression Scale) questionnaires, treatment compliance and nursing satisfaction. After intervention, the PFDI-20 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The PFIQ-7 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The HAMA and HAMD scores in the observation group were significantly lower than those in the control group (p < 0.05). The treatment compliance and nursing satisfaction rate of patients in the observation group were higher than those in the control group (p < 0.05). Health education based on the integrated theory of health behavior change can improve pelvic floor muscle strength, the quality-of-life, and the treatment compliance of patients after radical surgery for cervical cancer. In addition, this strategy can alleviate anxiety and depression, and improve nursing satisfaction and is worthy of wider clinical application.
{"title":"Application of health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery","authors":"","doi":"10.22514/ejgo.2023.062","DOIUrl":"https://doi.org/10.22514/ejgo.2023.062","url":null,"abstract":"To analyze the effect of applying health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery. We recruited 130 patients with cervical cancer who underwent gynecological surgery in our hospital between the 01 February 2021 and the 01 March 2022. According to the random number table method, the patients were divided into a control group and an observation group (65 cases per group). The control group received routine health education, while the observation group received health education based on the integrated theory of health behavior change. We compared the two groups with regards to pelvic floor function, quality-of-life, and psychological status before and after intervention by analyzing PFDI-20 (Pelvic Floor Distress Inventory Questionnaire-20), PFIQ-7 (Pelvic Floor Impact Questionnaire-7), HAMA (Hamilton Anxiety Scale) and HAMD (Hamilton Depression Scale) questionnaires, treatment compliance and nursing satisfaction. After intervention, the PFDI-20 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The PFIQ-7 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The HAMA and HAMD scores in the observation group were significantly lower than those in the control group (p < 0.05). The treatment compliance and nursing satisfaction rate of patients in the observation group were higher than those in the control group (p < 0.05). Health education based on the integrated theory of health behavior change can improve pelvic floor muscle strength, the quality-of-life, and the treatment compliance of patients after radical surgery for cervical cancer. In addition, this strategy can alleviate anxiety and depression, and improve nursing satisfaction and is worthy of wider clinical application.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Breast cancer is one of the most common malignant diseases, with a high mortality rate, affecting mostly females. This study aims to assess the diagnostic value of Molybdenum target X-ray examination and multimodality Magnetic Resonance Imaging (MRI) in breast cancer diagnosis. A total of 60 patients with suspected breast cancer were screened and included in the study. All patients underwent Molybdenum target X-ray and multimodality MRI, and the results were compared to pathological examination, which served as the reference standard for evaluating the diagnostic efficacy of the different screening methods. Molybdenum target X-ray examination identified 19 positive cases and 41 negative cases. Comparatively, multimodality MRI detected 43 positive cases and 17 negative cases. Compared to Molybdenum target X-ray, multimodality MRI demonstrated higher diagnostic accuracy, specificity, and sensitivity. Further analysis revealed that among the 45 positive patients, 13 were classified as stage 1, 20 as stage 2, 9 as stage 3, and 3 as stage 4. The pathological types were categorized as invasive ductal carcinoma, intraductal carcinoma, and ductal carcinoma in situ, with 25, 6 and 14 cases, respectively. Intraductal carcinoma exhibited higher levels of enhancement rate and signal enhancement ratio, as well as shorter peak time, compared to the other two types. No significant difference was observed between invasive ductal carcinoma and ductal carcinoma in situ. In the clinical diagnosis of breast cancer, multimodality MRI examination proves to be more comprehensive and accurate in determining the tumor’s nature and the type of disease, with significant clinical value in the field.
{"title":"Molybdenum target X-ray examination and multimodality MRI in the diagnosis of breast cancer","authors":"","doi":"10.22514/ejgo.2023.064","DOIUrl":"https://doi.org/10.22514/ejgo.2023.064","url":null,"abstract":"Breast cancer is one of the most common malignant diseases, with a high mortality rate, affecting mostly females. This study aims to assess the diagnostic value of Molybdenum target X-ray examination and multimodality Magnetic Resonance Imaging (MRI) in breast cancer diagnosis. A total of 60 patients with suspected breast cancer were screened and included in the study. All patients underwent Molybdenum target X-ray and multimodality MRI, and the results were compared to pathological examination, which served as the reference standard for evaluating the diagnostic efficacy of the different screening methods. Molybdenum target X-ray examination identified 19 positive cases and 41 negative cases. Comparatively, multimodality MRI detected 43 positive cases and 17 negative cases. Compared to Molybdenum target X-ray, multimodality MRI demonstrated higher diagnostic accuracy, specificity, and sensitivity. Further analysis revealed that among the 45 positive patients, 13 were classified as stage 1, 20 as stage 2, 9 as stage 3, and 3 as stage 4. The pathological types were categorized as invasive ductal carcinoma, intraductal carcinoma, and ductal carcinoma in situ, with 25, 6 and 14 cases, respectively. Intraductal carcinoma exhibited higher levels of enhancement rate and signal enhancement ratio, as well as shorter peak time, compared to the other two types. No significant difference was observed between invasive ductal carcinoma and ductal carcinoma in situ. In the clinical diagnosis of breast cancer, multimodality MRI examination proves to be more comprehensive and accurate in determining the tumor’s nature and the type of disease, with significant clinical value in the field.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patients with breast cancer (BC) have an increased risk of bone loss due to both the cancer itself and the side effects of antineoplastic therapies. This study evaluated the bone health of survivors of BC with germline pathogenic variants (PVs). This is a retrospective cross-sectional study. We identified 165 BC patients in whom PVs in BC susceptibility genes were diagnosed between February 2017 and December 2022 at our breast health center in Acibadem Altunizade Hospital. Only 80 patients underwent dual-energy X-ray absorptiometry (DXA) at the time of diagnosis. The median patient age was 44 years. Of 80 patients, 47% had (n = 38) had BRCA1 and BRCA2, while the remaining 53% (n = 42) had other PVs, which we refer to as non-BRCA. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) was performed in 21 patients with BRCA and 6 patients with non-BRCA PVs patients (p < 0.001). At the 68-months follow up period, a total of 53% had osteopenia, and 11% had osteoporosis. According to the mutation type, among patients with BRCA1 and BRCA2, 47% exhibited osteopenia and 11% had osteoporosis. In non-BRCA, 57% had osteopenia and 12% had osteoporosis (p > 0.05). In this study, we showed that patients with BRCA and non-BRCA mutations have similar rates of osteopenia and osteoporosis. This is particularly important for non-BRCA mutation carriers, because there is insufficient data on this subject.
{"title":"Evaluation of bone health in breast cancer patients with germline pathogenic","authors":"","doi":"10.22514/ejgo.2023.090","DOIUrl":"https://doi.org/10.22514/ejgo.2023.090","url":null,"abstract":"Patients with breast cancer (BC) have an increased risk of bone loss due to both the cancer itself and the side effects of antineoplastic therapies. This study evaluated the bone health of survivors of BC with germline pathogenic variants (PVs). This is a retrospective cross-sectional study. We identified 165 BC patients in whom PVs in BC susceptibility genes were diagnosed between February 2017 and December 2022 at our breast health center in Acibadem Altunizade Hospital. Only 80 patients underwent dual-energy X-ray absorptiometry (DXA) at the time of diagnosis. The median patient age was 44 years. Of 80 patients, 47% had (n = 38) had BRCA1 and BRCA2, while the remaining 53% (n = 42) had other PVs, which we refer to as non-BRCA. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) was performed in 21 patients with BRCA and 6 patients with non-BRCA PVs patients (p < 0.001). At the 68-months follow up period, a total of 53% had osteopenia, and 11% had osteoporosis. According to the mutation type, among patients with BRCA1 and BRCA2, 47% exhibited osteopenia and 11% had osteoporosis. In non-BRCA, 57% had osteopenia and 12% had osteoporosis (p > 0.05). In this study, we showed that patients with BRCA and non-BRCA mutations have similar rates of osteopenia and osteoporosis. This is particularly important for non-BRCA mutation carriers, because there is insufficient data on this subject.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Primary vaginal adenocarcinoma associated with human papillomavirus (HPV) infection is extremely rare. We report a case of primary adenocarcinoma of the vagina associated with human papilloma virus successfully treated with anterior pelvic exenteration and adjuvant concurrent chemoradiation therapy. A 51-year-old postmenopausal woman (gravida 1, para 1) presented with intermittent vaginal bleeding and pelvic pain. She was found to have a 5 × 5 cm necrotic tumor took up the vaginal. She had no previous history of antenatal exposure to diethylstilbestrol (DES). Pelvic magnetic resonance imaging (MRI) demonstrated a 4.8 × 6.0 cm mass in the vaginal canal, an 1.1 × 2.6 cm mass at the urinary bladder dome and a 1.1 cm irregular lymph node at the right external iliac chain with increased fluorodeoxyglucose (FDG) uptake from Fused whole-body positron emission tomography-computed tomography (PET-CT). Based on clinical investigations, the patient was diagnosed with a primary adenocarcinoma of vagina, staged International Fedestration of Gynecology and Obstetrics (FIGO) IVa. Anterior pelvic exenteration, simple vulvectomy, total vaginectomy, both pelvic lymph node dissection, and para-aortic lymph node dissection with ileal conduit urinary diversion (Bricker’s operation) was done. Histologically primary vaginal HPV type 16-associated adenocarcinoma was confirmed. Both obturator lymph node was positive for metastasis. Postoperatively, the patient received weekly cisplatin regimen administered with a dose of 40 mg/m2 on day 1 of external radiation therapy (RT), 1 to 4 hours before RT initiation. External beam pelvic RT dose prescription to the whole pelvis was 59.4 Gy in 33 fractions at the isocenter. But, after total dose of 43.2 Gy, patient complained severe bowel habit change and discontinued further treatment. The patient remains free from recurrence 8 months after initial surgery. In the lack of information and comparative analysis of management options for the more unusual and rare varieties of primary vaginal neoplasms in the literature, this suggests the possibility that surgical treatment may be preferentially selected on a case-by-case basis.
{"title":"Human papilloma virus associated primary vaginal adenocarcinoma","authors":"","doi":"10.22514/ejgo.2023.091","DOIUrl":"https://doi.org/10.22514/ejgo.2023.091","url":null,"abstract":"Primary vaginal adenocarcinoma associated with human papillomavirus (HPV) infection is extremely rare. We report a case of primary adenocarcinoma of the vagina associated with human papilloma virus successfully treated with anterior pelvic exenteration and adjuvant concurrent chemoradiation therapy. A 51-year-old postmenopausal woman (gravida 1, para 1) presented with intermittent vaginal bleeding and pelvic pain. She was found to have a 5 × 5 cm necrotic tumor took up the vaginal. She had no previous history of antenatal exposure to diethylstilbestrol (DES). Pelvic magnetic resonance imaging (MRI) demonstrated a 4.8 × 6.0 cm mass in the vaginal canal, an 1.1 × 2.6 cm mass at the urinary bladder dome and a 1.1 cm irregular lymph node at the right external iliac chain with increased fluorodeoxyglucose (FDG) uptake from Fused whole-body positron emission tomography-computed tomography (PET-CT). Based on clinical investigations, the patient was diagnosed with a primary adenocarcinoma of vagina, staged International Fedestration of Gynecology and Obstetrics (FIGO) IVa. Anterior pelvic exenteration, simple vulvectomy, total vaginectomy, both pelvic lymph node dissection, and para-aortic lymph node dissection with ileal conduit urinary diversion (Bricker’s operation) was done. Histologically primary vaginal HPV type 16-associated adenocarcinoma was confirmed. Both obturator lymph node was positive for metastasis. Postoperatively, the patient received weekly cisplatin regimen administered with a dose of 40 mg/m2 on day 1 of external radiation therapy (RT), 1 to 4 hours before RT initiation. External beam pelvic RT dose prescription to the whole pelvis was 59.4 Gy in 33 fractions at the isocenter. But, after total dose of 43.2 Gy, patient complained severe bowel habit change and discontinued further treatment. The patient remains free from recurrence 8 months after initial surgery. In the lack of information and comparative analysis of management options for the more unusual and rare varieties of primary vaginal neoplasms in the literature, this suggests the possibility that surgical treatment may be preferentially selected on a case-by-case basis.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}